[Pharmacological treatment of vascular cognitive impairment]
- PMID: 16969897
[Pharmacological treatment of vascular cognitive impairment]
Abstract
Vascular dementia is second most common cause of dementia. The paper highlights the most important trends in pharmacological treatment of vascular dementia. Result of a clinical trial of some agents appears to be promising. Pentoxifyline appears to be useful in multi-infarct vascular dementia. Nimodipine produced improvement in subcortical dementia. Some other agents like ginkgo biloba, acetylocholinesterase inhibitors, memantine and other also have shown mild benefit or at least were associated with some stabilization of dementia.
Similar articles
-
Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?J Neurol Sci. 2007 Jun 15;257(1-2):264-9. doi: 10.1016/j.jns.2007.01.043. Epub 2007 Feb 28. J Neurol Sci. 2007. PMID: 17331541 Review.
-
Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia.Am J Alzheimers Dis Other Demen. 2008 Apr-May;23(2):167-76. doi: 10.1177/1533317507312558. Epub 2008 Jan 9. Am J Alzheimers Dis Other Demen. 2008. PMID: 18184948 Free PMC article. Clinical Trial.
-
[Modern therapy for dementia].MMW Fortschr Med. 2005 May 17;147 Spec No 2:71-4, 76-7. MMW Fortschr Med. 2005. PMID: 15968877 German.
-
Drugs for cognitive loss and dementia.Treat Guidel Med Lett. 2010 Mar;8(91):19-24. Treat Guidel Med Lett. 2010. PMID: 20179667 Review. No abstract available.
-
Dementia.Clin Evid. 2004 Dec;(12):1361-90. Clin Evid. 2004. Update in: Clin Evid. 2005 Dec;(14):1198-220. PMID: 15865724 Updated. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical